SEC Comment Letter for Aptevo Therapeutics Inc. (APVO) (CIK 0001671584) (APVO) — Aug 27, 2026

Aptevo Therapeutics Inc. (APVO) (CIK 0001671584)
Date: Aug. 27, 2026 · CIK: 0001671584 · Accession: 0000000000-26-008467

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-298483

Date

August 27, 2026

Author

Division of

Form

UPLOAD

Company

Aptevo Therapeutics Inc. (APVO) (CIK 0001671584)

Letter

Re: Aptevo Therapeutics Inc. Registration Statement on Form S-1 Filed August 21, 2026 File No. 333-298483 Dear Jeffrey G. Lamothe: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions.

August 27, 2026

Jeffrey G. Lamothe President and Chief Executive Officer Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, WA 98121

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Sean M. Donahue, Esq.

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                            August 27, 2026

Jeffrey G. Lamothe
President and Chief Executive Officer
Aptevo Therapeutics Inc.
2401 4th Avenue, Suite 1050
Seattle, WA 98121

        Re: Aptevo Therapeutics Inc.
            Registration Statement on Form S-1
            Filed August 21, 2026
            File No. 333-298483
Dear Jeffrey G. Lamothe:
       This is to advise you that we have not reviewed and will not review your
registration
statement.
       Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you that
the company and its management are responsible for the accuracy and adequacy of
their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
       Please contact Jessica Dickerson at 202-551-8013 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:    Sean M. Donahue, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io